Prospects for the use of the drug formulation Depakine Chronosphere
- Authors: Vlasov PN1, Filatova NV1, Drozhzhina GR1, Vlasov PN1, Filatova NV1, Drojjina GR1
-
Affiliations:
- Issue: No 15 (2009)
- Pages: 43-47
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278023
- ID: 278023
Cite item
Full Text
Abstract
In clinical practice ideal antiepileptic drug (AED) must provide the concentration persistence in blood with a minimum number of intakes as well as such well-known characteristics, as high efficiency, wide spectrum of antiepileptic effects and high tolerability. High efficacy Depakine enteric and Depakin chrono (valproic acid preparations) is well known. New form of valproic acid medication Depakine Chronosphere combines the properties of Depakine chrono with best usability that significantly increases patient's treatment compliance. Easy dosage and treatment with Depakine Chronosphere makes it particularly prospective drug in the therapy of epilepsy, especially in children and elderly patients, i.e. patients requiring close control over regularity of receiving AED, because the efficacy of therapy depends on adherence to treatment.
Keywords
References
- Власов П.Н. Клиническая фармакология лекарственных средств, применяемых при судорожном синдроме. Глава 29 в кн. "Клиническая фармакология» национальное руководство. Национальный проект "Здоровье". М., 2008. 882 с.
- Власов П.Н., Орехова Н.В., Антонюк М.В. и др. Побочные эффекты вальпроатов. Клиническая эпилептология 2008 г. (в печати)
- Гусев Е.И., Гехт А.Б., Гуляева Н.В. и др. Эпилептические приступы у больных инсультом - факторы риска, патогенез и ведение больных. Эпилептология в медицине XXI века / Под ред. Е.И. Гусева, А.Б. Гехт. М., 2009. С. 179-181.
- Зенков Л.Р. Как улучшить лечение эпилепсии в России // РМЖ. 2003. № 1. С. 1-8.
- Карлов В.А. Стратегия и тактика терапии эпилепсии сегодня // Журнал невропатология и психиатрия. 2004. № 8. С. 28-34.
- Мухин К.Ю., Петрухин А.С., Миронов М.Б. Эпилептические синдромы. Диагностика и терапия (Справочное руководство для врачей). М., 2008. 223 с.
- Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-17.
- Dulac O. and Alvarez J-Claude. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- , or twice-daily administration. Pharmacotherapy 2005;25(1):35-42.
- Hirsch E., Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures. Does valproate have a lower potential? CNS Drugs 2003;17(3):633-40.
- Motte J. Acceptability and tolerability of a new microsphere formulation of sodium valproate (Depakine Chronosphere) in monotherapy for children with epilepsy. Epilepsia. 2005;46(Suppl. 6):810.
- Pellock JM, Smith MC, Cloyd JC, et al. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behavior 2004;5:301-07.
- Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning. Comparison with carbamazepine. Arch Neurol 1996;53:1008-16.
- The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical guideline 20. NICE. London 2004:73.
Supplementary files
